Alzheimer's Disease Cooperative Study
Company
Alzheimer's Disease Cooperative Study develops one asset, in phase 1 (ACI-24 in Down syndrome). Mostly vaccine acting on APP and proteostasis.
- 1
- Asset
- Furthest stage
- Phase 1
- 2
- Trials
- 0
- Signals
Pipeline
1Liposomal anti-amyloid-beta vaccine designed to elicit antibodies against amyloid-beta to prevent or clear plaques
Phase 1, Vaccine, APP, Proteostasis, Down syndrome, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials7
- Similar companies6
Papers
AAIC 2025 abstract, 25 Dec 2025
Impact of Neuropsychiatric Symptoms on Measures of Daily Functioning in Older Adults
AAIC 2025 abstract, 25 Dec 2025